<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559117</url>
  </required_header>
  <id_info>
    <org_study_id>GT-111001 (VB-111)</org_study_id>
    <nct_id>NCT00559117</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Biogenics Ltd. operating as VBL Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Biogenics Ltd. operating as VBL Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in
      Patients with Advanced Metastatic Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nine Cohorts of dose escalating VB-111 were completed with a total of 56 subjects enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced and/or Metastatic Solid Organ Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB-111</intervention_name>
    <description>A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years of age

          -  Histologically confirmed malignancy that is metastatic or unresectable and for which
             standard curative or palliative measures do not exist or are no longer effective. For
             Cohort 8, malignancy will include only NET or RCC.

          -  Karnofsky performance status of ≥70%

          -  Patients with an adequate hematological profile

          -  Patients with an adequate renal function

          -  Males and Females of childbearing potential must utilize a standard contraception
             method

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Pregnant or breastfeeding patients

          -  Patients, who suffered from an acute cardiac event within the last 12 months

          -  Patients with active vascular disease, either myocardial or peripheral

          -  Patients with proliferative and/or vascular retinopathy

          -  Patients with known liver disease (alcoholic, drug/toxin induced, genetic, or
             autoimmune)

          -  Patients with known CNS metastatic disease

          -  Patients testing positive to one of the following viruses: HIV, HBV or HCV

          -  Patients receiving chemotherapy or radiotherapy within the last 4 weeks before
             enrolment

          -  Patients that have undergone major surgery within the last 4 weeks before enrolment

          -  Patients may not have received anti-angiogenic therapy within the previous 8 weeks
             before enrolment.

          -  Patients may not have received any other investigational agent within 4 weeks before
             enrolment.

          -  Patients with an ongoing requirement for an immunosuppressive treatment, including the
             use of glucocorticoids or cyclosporin, or with a history of chronic use of any such
             medication within the last 4 weeks before enrolment

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Triozzi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSC- CTRC and Institute for Drug Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber/Brigham and Women's Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTHSC- CTRC and Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

